相似文献
1
Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples.
JAMA. 2021 Jul 21;326(9):868-9. doi: 10.1001/jama.2021.11656.
2
Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
Viruses. 2021 Oct 6;13(10):2011. doi: 10.3390/v13102011.
3
Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients - implications for the omicron variant.
J Heart Lung Transplant. 2022 Oct;41(10):1417-1425. doi: 10.1016/j.healun.2022.05.014. Epub 2022 May 24.
4
A Beta Strain-Based Spike Glycoprotein Vaccine Candidate Induces Broad Neutralization and Protection against SARS-CoV-2 Variants of Concern.
Microbiol Spectr. 2023 Feb 27;11(2):e0268722. doi: 10.1128/spectrum.02687-22.
5
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.
Microbiol Spectr. 2021 Dec 22;9(3):e0056121. doi: 10.1128/Spectrum.00561-21. Epub 2021 Dec 1.
6
Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
Emerg Microbes Infect. 2022 Dec;11(1):543-547. doi: 10.1080/22221751.2022.2035195.
7
Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant.
Emerg Infect Dis. 2022 Aug;28(8):1708-1712. doi: 10.3201/eid2808.220584. Epub 2022 Jul 13.
8
Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine.
Microbiol Spectr. 2022 Oct 26;10(5):e0204622. doi: 10.1128/spectrum.02046-22. Epub 2022 Oct 3.
9
Live-virus neutralization of the omicron variant in children and adults 14 months after SARS-CoV-2 wild-type infection.
J Med Virol. 2023 Mar;95(3):e28582. doi: 10.1002/jmv.28582.
10
Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.
Microbiol Spectr. 2023 Feb 21;11(2):e0344522. doi: 10.1128/spectrum.03445-22.
引用本文的文献
1
Dynamics of neutralizing antibodies against COVID-19 Omicron subvariants following breakthrough infection in southwest China between December 2022 and April 2024.
Signal Transduct Target Ther. 2025 Jul 30;10(1):242. doi: 10.1038/s41392-025-02319-3.
2
Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.
Front Immunol. 2025 May 14;16:1584876. doi: 10.3389/fimmu.2025.1584876. eCollection 2025.
3
Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR Repertoires.
bioRxiv. 2023 Sep 11:2023.09.08.556703. doi: 10.1101/2023.09.08.556703.
4
SARS-CoV-2 Immunization Index in the Academic Community: A Retrospective Post-Vaccination Study.
Infect Dis Rep. 2024 Nov 25;16(6):1084-1097. doi: 10.3390/idr16060088.
5
Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals.
Open Forum Infect Dis. 2024 Sep 9;11(10):ofae527. doi: 10.1093/ofid/ofae527. eCollection 2024 Oct.
6
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination.
Vaccines (Basel). 2024 May 22;12(6):564. doi: 10.3390/vaccines12060564.
7
T cell hybrid immunity against SARS-CoV-2 in children: a longitudinal study.
EBioMedicine. 2024 Jul;105:105203. doi: 10.1016/j.ebiom.2024.105203. Epub 2024 Jun 18.
8
Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.
9
SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.
Sci Rep. 2024 Apr 18;14(1):8426. doi: 10.1038/s41598-024-58811-3.
10
Humoral Immune Responses following COVID-19 Vaccinations among Adults in Tanzania.
Vaccines (Basel). 2023 Dec 23;12(1):22. doi: 10.3390/vaccines12010022.
本文引用的文献
1
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021.
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793. doi: 10.15585/mmwr.mm7021e3.
2
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.
3
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
4
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
5
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
6
Excess mortality in England and Wales during the first wave of the COVID-19 pandemic.
J Epidemiol Community Health. 2021 Mar;75(3):213-223. doi: 10.1136/jech-2020-214764. Epub 2020 Oct 15.
Zotero 插件